Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 5S ribosomal pseudogene 349 (RNA5SP349) is a non-coding RNA segment classified as a processed pseudogene derived from the 5S ribosomal RNA gene family[3][4][5]. Processed pseudogenes arise via reverse transcription and reinsertion into the genome; they typically lack introns, have sequence homology to their parent gene, and do not encode functional RNA or protein due to accumulated mutations[2][4]. While some pseudogenes have been found to be transcribed and implicated in biological regulation or disease correlation, the majority, including RNA5SP349, are not considered therapeutically actionable targets and do not participate in established biological processes[2][3][4][5][6]. Pseudogene expression profiles may offer utility as research biomarkers across cancer and other diseases, but there is no direct evidence for a functional or mechanistic role for RNA5SP349 in cell biology or disease[6].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 5S ribosomal pseudogene 349 (RNA5SP349).